Home

Articles from Scale Biosciences, Inc.

Scale Bio Joins Chan Zuckerberg Initiative's Billion Cells Project, Accelerating Single Cell Research at Unprecedented Scale
Scale Biosciences, Inc. (Scale Bio), a leader in highly scalable single cell technologies, today announced its participation in the Chan Zuckerberg Initiative's (CZI) Billion Cells Project at the Chan Zuckerberg Biohub New York Affiliate Symposium. Scale Bio joins technology partners 10x Genomics and Ultima Genomics in this landmark effort to generate an unprecedented one billion cell dataset to fuel rapid progress in cell biology through AI model development. This collaboration represents a significant expansion of the data generation capabilities for the Billion Cells Project.
By Scale Biosciences, Inc. · Via Business Wire · April 3, 2025
Scale Biosciences Continues Commercial Expansion with Introduction of New and Differentiated Single Cell Methylation and Single Cell RNA Sequencing Solutions
Scale Biosciences, Inc. (ScaleBio™), an innovator in single cell sequencing leveraging combinatorial indexing technologies, today announced an expansion of their product portfolio to enable a broader range of single cell omics experiments and unlock new translational research applications. New products include the ScaleBio Single Cell Methylation Kit, ScaleBio Single Cell CRISPR Guide Enrichment Kit, Scale-plex Kit, and additional capabilities for the company’s existing ScaleBio Single Cell RNA Sequencing Kit to facilitate more diverse experimental designs and broader use of translational samples leveraging innovative, scalable, and accessible tools to democratize single cell omics across research applications without the need for additional instrumentation. Together, these kit-based products expand researchers' ability to profile cells and tissues, and to uncover novel cell types and states with their functions.
By Scale Biosciences, Inc. · Via Business Wire · August 29, 2023
Scale Biosciences (ScaleBio) Introduces New Disruptive Single-Cell Profiling and Analysis Solutions, Sets New Standards
Scale Biosciences, Inc. (ScaleBio), a pioneer in single-cell sequencing and combinatorial indexing technologies, has transitioned from research and development to commercial stage with the release of its first generation single-cell transcriptomics scRNAseq profiling and analysis solution, establishing new standards for accessible, scalable, and low-cost single-cell sequencing.
By Scale Biosciences, Inc. · Via Business Wire · December 15, 2022